Literature DB >> 25249768

Association of T174M polymorphism of angiotensinogen gene with essential hypertension: A meta-analysis.

Xiaoyang Liao1, Zhiyi Yang1, Daqing Peng1, Hua Dai1, Yi Lei1, Qian Zhao1, Yanbing Han1, Weiwen Wang2.   

Abstract

The association between T174M polymorphism of angiotensinogen gene and essential hypertension risk remains controversial. We herein performed a meta-analysis to achieve a reliable estimation of their relationship. All the studies published up to May 2013 on the association between T174M polymorphism and essential hypertension risk were identified by searching the electronic repositories PubMed, MEDLINE and EMBASE, Springer, Elsevier Science Direct, Cochrane Library and Google Scholar. Data were extracted and pooled odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated. Ultimately, nine eligible studies, including 2188 essential hypertension cases and 2459 controls, were enrolled in this meta-analysis. No significant associations were found under the overall ORs for M-allele comparison (M vs. T, pooled OR 0.92, 95% CI 0.62-1.37), MM vs. TT (pooled OR 0.86, 95% CI 0.29-2.51), TM vs. TT n (pooled OR 0.91, 95% CI 0.63-1.32), recessive model (MM vs. TT+TM, pooled OR 0.89, 95% CI 0.35-2.30), dominant model (MM+TM vs. TT, pooled OR 0.91, 95% CI 0.60-1.38) between T174M polymorphism and risk for essential hypertension. This meta-analysis suggested that the T174M polymorphism of the angiotensinogen gene might not be associated with the susceptibility of essential hypertension in Asian or European populations.

Entities:  

Keywords:  T174M; case-control study; essential hypertension; meta-analysis; polymorphism

Year:  2014        PMID: 25249768      PMCID: PMC4171772          DOI: 10.1590/s1415-47572014000400001

Source DB:  PubMed          Journal:  Genet Mol Biol        ISSN: 1415-4757            Impact factor:   1.771


Introduction

Hypertension affects approximately 30% of adults in industrialized countries and is the major risk factor for cardiovascular disease (Nguyen ). Hypertension is classified into essential hypertension and secondary hypertension according to the etiology. Secondary hypertension is a type of hypertension caused by an identifiable underlying secondary cause, such as renovascular disease, renal failure, pheochromocytoma, aldosteronism and others, while essential hypertension is defined as hypertension in which secondary causes are not present (Carretero and Oparil, 2000). More than 90% of all hypertensive persons are reported to have essential hypertension (Ghosh ). Essential hypertension is associated with large and small vascular remodeling that impacts cardiovascular prognosis (Briet and Schiffrin, 2013). It is generally considered as a paradigmatic multi-factors disease which involves a combination of genetic factors, environmental stimuli and their interaction (O’Shaughnessy, 2001). It has been reported that approximately 20–60% of the inter-individual variation in blood pressure is genetically controlled (Kurtz and Spence, 1993). Thus, we hypothesized that exploring potential hypertension susceptibility genes would help us to better understand the etiology of the disease and, eventually, to better control this disease. Angiotensinogen (AGT) is a liver protein that interacts with renin to produce angiotensin I, the prohormone of angiotensin II, which is the major effector molecule of the renin-angiotensin-aldosterone system (Gu ). It is a promising candidate gene for evaluating susceptibility to essential hypertension (Mohana ). T174M polymorphism refers to the substitution of threonine to methionine amino acid at position 174 in exon 2 of the AGT gene. A significant association between T174M polymorphism and the risk of essential hypertension has been reported in several studies (Iso ; Jiang ). However, several other studies did not detect such an association (Sato ; Wang ; Nejatizadeh ). Therefore, the T174M polymorphism was conflictingly associated with essential hypertension. In order to achieve an integrative understanding of the association between the T174M polymorphism and the risk of essential hypertension it is necessary to consider the findings as a whole, paying special attention to methodological characteristics of each of the studies. Accordingly, we conducted a systematic review of published findings and used meta-analysis techniques to quantitatively combine the results. This allowed us comprehensively investigate the association between T174M polymorphism and the risk of essential hypertension.

Materials and Methods

Sources for the literature search

A literature search was conducted for studies that reported the effect of T174M polymorphism on the risk of essential hypertension. We systematically searched the PubMed, MEDLINE and EMBASE, Springer, Elsevier Science Direct, Cochrane Library and Google Scholar electronic databases for articles published up to May 2013. The following key words were used for searching: “T174M”, “hypertension”, “angiotensinogen gene”, “polymorphism”, “variants”, “study” or “trial”. Furthermore, complimentary searches in the references lists of retrieved papers were performed for any additional studies. The research was restricted to full-text English-language articles of studies in humans.

Search methods

Six investigators (XY. L, ZY. Y, DQ. P, H. D, Y. L and Q. Z) independently searched the electronic databases. The abstracts were first reviewed to obtain potentially eligible articles according to the inclusion criteria. To avoid a possible loss of any relevant article, an additional search was performed through the references cited in identified articles.

Included and excluded criteria of studies

Inclusion criteria of studies

Studies were included in the current meta-analysis if they met the following criteria: (1) the investigated patients suffered from essential hypertension (prospective studies, retrospective studies, or cross-sectional studies, etc.); (2) they evaluated the relationship between T174M polymorphism and essential hypertension risk; (3) they had an odds ratio (OR) with an 95% confidence interval (CI), or other available information for estimating the OR (95% CI); (4) they provided available genotype data for the T174M polymorphism.

Exclusion criteria of studies

Studies were excluded if they met the following criteria: (1) they were designed based on family or sibling pairs; (2) the genotype frequency of the T174M polymorphism was not reported; (3) they did not detect an association between T174M polymorphism and susceptibility of essential hypertension; (4) there was insufficient information for extraction of data.

Evaluation of quality and extraction of data

The quality of the included studies was assessed using a ten-point scoring sheet, as previously described (Clark and Baudouin, 2006). The factors including control group, Hardy-Weinberg equilibrium, case group, primer, reproducibility, blinding, power calculation, statistics, corrected statistics and independent replication were evaluated and the score was recorded as 1 if present or 0 if absent. A final quality score was obtained by summation of each component. Two investigators completed the evaluation independently, and any difference was settled by discussion to reach an agreement between these two investigators. Two investigators (XY. L and H. Y) independently extracted data according to the inclusion criteria listed above. The extracted data included the first author’s name, year of publication, country, sample size, participants, study design, genotyping methods, source of control group, and distribution of T174M polymorphism within the participants of the case vs. control group in all studies. Some of these data items were obtained from the author of the primary study. Disagreements were resolved by discussion and reaching an agreement among all investigators, or by contacting the original investigators.

Meta-analysis methods

The strength of the association between T174M polymorphisms and essential hypertension risk was determined by an OR with 95% CI. A chi-square test was used to determine whether or not the observed frequencies of genotypes in the controls conformed to HWE (Hardy-Weinberg expectations), and a p-value < 0.05 was considered as significant disequilibrium. Pooled ORs were calculated to examine the contrast of A-allele comparison (M vs. T), MM vs. TT, TM vs. TT, recessive model (MM vs. TT+TM) and dominant model (MM+TM vs. TT), respectively. The significance of pooled ORs was determined by a Z-test and a p-value < 0.05 was considered as statistically significant. We assessed the within- and between-study variation or heterogeneity by Cochran’s Q-statistic testing (Deeks ) and calculating the I2 index (I2 = 100%(Q-df)/Q) (Higgins ). A significant Q-statistic (p < 0.10) or I2 > 50% indicated heterogeneity across studies, so the pooled OR estimate was calculated using the random-effects (DerSimonian and Laird, 1986). Otherwise, the fixed-effect (Mantel and Haenszel, 1959) was used. Publication bias was evaluated by using the Egger’s linear regression test (Egger ), which measures funnel plot asymmetry on the natural logarithm scale of the effect size. Analyses were performed using the STATA software package v.11.0 (Stata Corporation, College Station, TX, USA).

Results

Characteristics of the eligible studies

We retrieved 1037 records that were potentially relevant to the search terms (PubMed: 312; MEDLINE: 136; Springer: 198; Elsevier Science Direct: 105; Cochrane Library: 21; Google Scholar: 265). The study selection process is summarized in Figure 1. After duplicates were removed, this number went down to 129 potentially relevant studies. By screening the abstracts, 89 of these articles were excluded, these including 31 review articles, 23 articles irrelevantto the T174M gene, and 35 articles irrelevantto essential hypertension. The remaining 40 studies were then examined in detail by full text review, this leading to the exclusion of 31 articles, including 17 publications that not about the T174M gene and 14 for not showing available data.
Figure 1

Flowchart of the selection of studies for inclusion in the meta-analysis.

Flowchart of the selection of studies for inclusion in the meta-analysis. The final result were nine studies (Iso ; Sato ; Vasku ; Wang ; Nair ; Tsai ; Nejatizadeh et al.,2008; Jiang ; Yuan ). These involved 2188 essential hyper cases and 2459 controls, and by meeting the inclusion criteria they were included in this meta-analysis. All of them were case-control studies. The characteristics of these selected studies are summarized in Tables 1 and 2. The included studies were published between 2000 and 2009. The sample sizes ranged from 203 to 919, and source of control groups were normotensives. Eight studies were conducted in Asian populations and one in a European. Furthermore, the observed genotype counts for T174M polymorphisms in each study were all consistent with Hardy-Weinberg disequilibrium (p > 0.05).
Table 1

Characteristics of studies included in the meta-analysis.

StudyYearCountryEthnicityGenotyping methodsSample size
Source of controlStudy design
CaseControl
Iso et al., 20002000JapanAsianNA229690NormotensivesCase-control
Jiang et al., 2009 112008ChinaAsianMultiplex PCR220235NormotensivesCase-control
Nair et al., 20032003IndiaAsianPCR-based restriction endonuclease digestion method134131NormotensivesCase-control
Nejatizadeh et al., 20082008IndiaAsianNA450358NormotensivesCase-control
Sato et al., 20002000JapanAsianPCR-RFLP180195NormotensivesCase-control
Tsai et al., 20032003ChinaAsianMini-PCR408286NormotensivesCase-control
Vasku et al., 20022002Czech RepublicEuropeanNA189201NormotensivesCase-control
Wang et al., 20022002ChinaAsianPCR amplifications10796NormotensivesCase-control
Yuan et al., 20092009ChinaAsianPCR-RFLP271267NormotensivesCase-control
Table 2

Genotype frequencies of T174M polymorphism in studies included in the meta-analysis.

StudyYear of publicationCase genotypeControl genotypeHWEa



TTTMMMTTTMMMChi-square testp value
Iso et al., 20002000177502335289660.100.74
Jiang et al., 200920091268591676350.110.73
Nair et al., 200320031042911022720.010.88
Nejatizadeh et al., 200820083786752916161.730.19
Sato et al., 200020001453141553820.040.84
Tsai et al., 2003200332670122315320.310.58
Vasku et al., 200220021424431475040.010.92
Wang et al., 2002200291151791610.040.85
Yuan et al., 200920092274402353201.080.29

HWE: Hardy-Weinberg equilibrium, evaluated using the goodness-of-fit chi-square test. p < 0.05 was considered representative of a departure from HWE.

Characteristics of studies included in the meta-analysis. Genotype frequencies of T174M polymorphism in studies included in the meta-analysis. HWE: Hardy-Weinberg equilibrium, evaluated using the goodness-of-fit chi-square test. p < 0.05 was considered representative of a departure from HWE.

Meta-analysis of the association between T174M polymorphism and risk for essential hypertension

Crude ORs with 95% CIs were used to assess the association between T174M polymorphism and risk of essential hypertension. Significant heterogeneities were observed across the studies for M-allele comparison (M vs. T, p < 0.01 and I2 = 88.2%), MM vs. TT comparison (p < 0.01 and I2 = 73.0%), TM vs. TT comparison (p < 0.01 and I2 = 82.9%), recessive model (MM vs. TT+TM, p < 0.01 and I2 = 65.4%) and dominant model (MM+TM vs. TT, p < 0.01 and I2 = 87.1%) (Table 3). Therefore, the random effect model was applied to estimate the overall ORs.
Table 3

Meta-analysis of the association between T174M polymorphism and risk of essential hypertension using random effect model.

GroupsNo. of studiesM vs. TMM vs. TTTM vs. TTMM vs. TT+TMMM+TM vs. TT





OR(95%CI)PAI2 (%)PHOR(95%CI)PAI2 (%)PHOR(95%CI)PAI2 (%)PHOR(95%CI)PAI2 (%)PHOR(95%CI)PAI2 (%)PH
Overall90.92 (0.62, 1.37)0.6988.2< 0.010.86 (0.29, 2.51)0.7873.0< 0.010.91 (0.63, 1.32)0.6282.9< 0.010.89 (0.35, 2.30)0.8165.4< 0.010.91 (0.60, 1.38)0.6587.1< 0.01
Ethnicity
Asian80.93 (0.59, 1.44)0.7389.6< 0.010.87 (0.25, 3.04)0.8377.0< 0.010.91 (0.60, 1.38)0.6685.0< 0.010.91 (0.30, 2.74)0.8670.5< 0.010.91 (0.57, 1.46)0.788.7< 0.01
European10.90 (0.60, 1.36)0.63--0.78 (0.17, 3.53)0.74--0.91 (0.57, 1.45)0.70--0.79 (0.18, 3.60)0.77--0.90 (0.57, 1.42)0.65--
Sample size
< 50051.09 (0.82, 1.45)0.5347.00.111.46 (0.70, 3.02)0.310.00.641.09 (0.79, 1.51)0.6047.20.111.36 (0.66, 2.81)0.410.00.741.10 (0.79, 1.53)0.5851.50.08
≥50040.79 (0.39, 1.60)0.5293.5< 0.010.53 (0.05, 5.76)0.6188.9< 0.010.77 (0.41, 1.43)0.4189.7< 0.010.61 (0.07, 5.27)0.6586.6< 0.010.76 (0.37, 1.56)0.4592.7< 0.01

OR, odds ratio; CI, confidence interval; pH, p value for between-study heterogeneity; PA, p value for test of the association.

Meta-analysis of the association between T174M polymorphism and risk of essential hypertension using random effect model. OR, odds ratio; CI, confidence interval; pH, p value for between-study heterogeneity; PA, p value for test of the association. In the present study, no significant difference was observed in the risk of essential hypertension between the genotypes M vs. T (pooled OR 0.92, 95% CI 0.62–1.37), MM vs. TT (pooled OR 0.86, 95% CI 0.29–2.51), TM vs. TT (pooled OR 0.91, 95% CI 0.63–1.32), MM vs. TT+TM (pooled OR 0.89, 95% CI 0.35–2.30), or MM+TM vs. TT (pooled OR 0.91, 95% CI 0.60–1.38) (Table 3). We also performed a subgroup analysis stratified by geographic location (ethnicity) and sample size. As shown in Table 3, this refined further analysis still did not indicated an association between T174M polymorphism and essential hypertension risk.

Publication bias

The Egger’s test was performed to assess the publication bias of the published studies. For all comparisons, the p value of the Egger’s test was higher than 0.05 (Table 4), this indicating that there was no evident publication bias in this meta-analysis.
Table 4

Tests for publication bias (Egger’s test) in population (overall).

ComparisonEgger’s test
tp value
M vs. T0.760.47
MM vs. TT−0.200.85
TM vs. TT0.840.43
MM vs. TT+TM−0.160.88
MM+TM vs. TT0.840.43
Tests for publication bias (Egger’s test) in population (overall).

Discussion

The association between the T174M polymorphism and risk for essential hypertension was not clear due to inconsistent data generated by a range of independent studies (Nair ; Tsai ; Jiang ; Nejatizadeh ). Therefore, we performed a meta-analysis of published studies to clarify the inconsistency and to establish a comprehensive picture of this gene-disease association. All studies included in this analysis were conducted in Asian or European populations with high prevalence of essential hypertension. In our meta-analysis, a total of nine studies were included, these comprising 2188 cases and 2459 controls. The conclusion is that no significant association was detected between the T174M polymorphism and essential hypertension risk. The findings of the present study were different from the results of a previous meta-analysis conducted by Pereira , in which a codominant model of T174M polymorphism demonstrated a significant increase in the risk of essential hypertension in Asians (10 studies were included and four of them were Chinese) and in mixed/other populations (including African, Indo-European/East Asian, Russian Arab and Turkish) but not in a population of European descendants. Upon comparing these two meta-analyses, we found that two studies (Morise ; Yi-Yang ) conducted among Asian populations (one in Japan and one in Chain) were included in the analysis of Pereira but not in ours. These two studies indicated a significantly increased risk of essential hypertension among populations carrying the 174M allele. This may be one reason for the different outcomes of these two meta-analyses. Furthermore, it should be noted that in the study of Pereira a potential publication bias was present. The AGT gene T174M polymorphism was first reported by Jeunemaitre to be related to the prevalence of essential hypertension. Since then several studies on this relationship, enrolling various ethnic groups, have been published. Some studies confirmed the association between T174M variant and hypertension(Gardemann ; Procopciuc ), but others did not (Nair ; Renner ). Moreover, some studies reached different conclusions, even when they were performed among the same ethnic populations (Qi ; Gu ). There are several potential explanations for the discrepancies among these studies. The first possible cause may be genetic differences in the population samples and phenotypic differences in the hypertensive populations analyzed (Marco ). Second, the effect of the T174M variant on plasma AGT levels may vary among different ethnic groups so that the association between T174M polymorphism and risk of essential hypertension may not be detected in every ethnic group, just as shown in the study of Pereira . Most studies included in current meta-analysis were conducted in Asian populations and only one in a European population, this meaning that the final result may not be generalizable. Therefore, more studies need to be performed in various ethnic groups and subgroup analysis stratified by ethnicity should be conducted in future research. Second, the reliability of the findings of a study may be questionable if it lacks an appropriate control group. In some studies, the age and percentage of subjects with alcohol consumption or smoking were significantly different between the hypertensive and control groups (Hingorani ; Kiema ). A third possible cause of discrepancy may be a multiple interaction of polymorphisms or genes. These gene-to-gene interactions make the association of hypertension with any single candidate gene more complex (Wang ). In addition, the numbers of cases were different in various studies, this leading to variation in precision. Finally, hypertension is an acknowledged multi-factorial disease. Genetic factors may interact with several other factors, such as salt intake, body mass index, and smoking in the development of hypertension. Certain limitations of this study need to be mentioned. First of all, heterogeneity across the studies was observed. One possible reason for the presence of heterogeneity is the wide variation in populations included (77.7% in Asian and 11.1% in European). Second, the effect of genetic and environmental interactions was not considered. In addition, all the included articles were case-control studies and the number of studies was small (nine). Therefore, more and high-quality case-control studies are still needed to test and verify the results of this metaanalysis. Finally, our analysis was limited to eight studies on Asian and one on European populations, which is certainly not representative of all ethnicities. The association between the T174M polymorphism and risk of essential hypertension still needs to be clarified. Despite these limitations, this meta-analysis suggests that the T174M polymorphism of the angiotensinogen gene is not associated with susceptibility of essential hypertension, and the allele M may not increase the risk of essential hypertension in Asian or European populations. Considering the different genetic and phenotypic features among different ethnic groups, larger and well-designed studies based on different populations are needed to confirm our results.
  32 in total

1.  Association between the angiotensinogen gene T174M polymorphism and hypertension risk in the Chinese population: a meta-analysis.

Authors:  Wei Gu; Ya Liu; Zuoguang Wang; Kuo Liu; Yuqing Lou; Qiuli Niu; Hao Wang; Jinghua Liu; Shaojun Wen
Journal:  Hypertens Res       Date:  2011-09-01       Impact factor: 3.872

2.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

3.  Effects of rare and common blood pressure gene variants on essential hypertension: results from the Family Blood Pressure Program, CLUE, and Atherosclerosis Risk in Communities studies.

Authors:  Khanh-Dung H Nguyen; Vasyl Pihur; Santhi K Ganesh; Ankit Rakha; Richard S Cooper; Steven C Hunt; Barry I Freedman; Joe Coresh; W H Linda Kao; Alanna C Morrison; Eric Boerwinkle; Georg B Ehret; Aravinda Chakravarti
Journal:  Circ Res       Date:  2012-11-12       Impact factor: 17.367

4.  Nine polymorphisms of angiotensinogen gene in the susceptibility to essential hypertension.

Authors:  N Sato; T Katsuya; T Nakagawa; K Ishikawa; Y Fu; T Asai; M Fukuda; F Suzuki; Y Nakamura; J Higaki; T Ogihara
Journal:  Life Sci       Date:  2000-12-08       Impact factor: 5.037

5.  Angiotensinogen T174M and M235T gene polymorphisms are associated with the extent of coronary atherosclerosis.

Authors:  A Gardemann; J Stricker; J Humme; Q D Nguyen; N Katz; M Philipp; H Tillmanns; F W Hehrlein; W Haberbosch
Journal:  Atherosclerosis       Date:  1999-08       Impact factor: 5.162

Review 6.  Treatment of arterial remodeling in essential hypertension.

Authors:  Marie Briet; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2013-02       Impact factor: 5.369

7.  Coronary heart disease, hypertension, and angiotensinogen gene variants in Indian population.

Authors:  K G Nair; K K Shalia; T F Ashavaid; J J Dalal
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

8.  Diagnosis of essential hypertension in humans by the determination of plasma renal cortexin using enzyme-linked immunosorbent assay.

Authors:  Rajeshwary Ghosh; Mau Bhattacharyya; Gausal Khan; Somashree Chakraborty; Rabindra Bhattacharya; Uttam K Maji; Pradipta Jana; Asru K Sinha
Journal:  Clin Lab       Date:  2013       Impact factor: 1.138

9.  Angiotensinogen gene haplotype and hypertension: interaction with ACE gene I allele.

Authors:  Chia-Ti Tsai; Daniele Fallin; Fu-Tien Chiang; Juey-Jen Hwang; Ling-Ping Lai; Kuan-Lih Hsu; Chuen-Den Tseng; Chiau-Suong Liau; Yung-Zu Tseng
Journal:  Hypertension       Date:  2003-01       Impact factor: 10.190

10.  Angiotensinogen T174M and M235T variants and hypertension in the Hani and Yi minority groups of China.

Authors:  Jiali Yuan; Wenru Tang; Yinan Chun; Hua Ying; Yang Yang; Chunjie Xiao
Journal:  Biochem Genet       Date:  2009-04-14       Impact factor: 1.890

View more
  2 in total

Review 1.  Genetics of Human Primary Hypertension: Focus on Hormonal Mechanisms.

Authors:  Worapaka Manosroi; Gordon H Williams
Journal:  Endocr Rev       Date:  2019-06-01       Impact factor: 19.871

Review 2.  Role of environmental toxicants in the development of hypertensive and cardiovascular diseases.

Authors:  Ehsan Habeeb; Saad Aldosari; Shakil A Saghir; Mariam Cheema; Tahani Momenah; Kazim Husain; Yadollah Omidi; Syed A A Rizvi; Muhammad Akram; Rais A Ansari
Journal:  Toxicol Rep       Date:  2022-03-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.